CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 3, Issue 3, 2009, Pages 175-182

  Gordon, J N ^a,e   Prothero, J D ^a   Thornton, C A ^b   Pickard, K M ^a   Di Sabatino, A ^a   Goggin, P M ^c   Pender, S L ^a   MacDonald, T T ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Matrix metalloproteinase; Thalidomide; Thalidomide derivatives; Ulcerative colitis

Indexed keywords

CC 10004; LENALIDOMIDE; PHOSPHODIESTERASE IV INHIBITOR; POMALIDOMIDE; STROMELYSIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LAMINA PROPRIA; MONONUCLEAR CELL; MYOFIBROBLAST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 67651119981     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.03.001     Document Type: Article

References (45)

1. Braegger C.P., Nicholls S., Murch S.H., Stephens S., and MacDonald T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339 8785 (1992) 89-91
2. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106 6 (1994) 1455-1466
3. Murch S.H., Lamkin V.A., Savage M.O., Walker-Smith J.A., and MacDonald T.T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32 8 (1991) 913-917
4. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 15 (1997) 1029-1035
5. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
6. Pender S.L., and MacDonald T.T. Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol 4 6 (2004) 546-550
7. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 31 (1999) 21491-21494
8. Baugh M.D., Evans G.S., Hollander A.P., Davies D.R., et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci 859 (1998) 249-253
9. Baugh M.D., Perry M.J., Hollander A.P., Davies D.R., et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 4 (1999) 814-822
10. von Lampe B., Barthel B., Coupland S.E., Riecken E.O., and Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47 1 (2000) 63-73
11. Louis E., Ribbens C., Godon A., Franchimont D., et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 120 2 (2000) 241-246
12. Salmela M.T., MacDonald T.T., Black D., Irvine B., et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 51 4 (2002) 540-547
13. Heuschkel R.B., MacDonald T.T., Monteleone G., Bajaj-Elliott M., Smith J.A., and Pender S.L. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47 1 (2000) 57-62
14. Kirkegaard T., Hansen A., Bruun E., and Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53 5 (2004) 701-709
15. Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., and MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158 4 (1997) 1582-1590
16. Pender S.L., Fell J.M., Chamow S.M., Ashkenazi A., and MacDonald T.T. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 160 8 (1998) 4098-4103
17. Kobayashi K., Arimura Y., Goto A., Okahara S., et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol 209 3 (2006) 376-383
18. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 3 (1991) 699-703
19. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., Hassard P.V., et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117 6 (1999) 1278-1287
20. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., and Hanauer S.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 6 (1999) 1271-1277
21. Bariol C., Meagher A.P., Vickers C.R., Byrnes D.J., et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 17 2 (2002) 135-139
22. Sabate J.M., Villarejo J., Lemann M., Bonnet J., Allez M., and Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 16 6 (2002) 1117-1124
23. Bauditz J., Wedel S., and Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50 2 (2002) 196-200
24. Lazzerini M., Martelossi S., Marchetti F., Scabar A., et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 25 4 (2007) 419-427
25. Plamondon S., Ng S.C., and Kamm M.A. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 25 5 (2007) 557-567
26. Dredge K., Marriott J.B., and Dalgleish A.G. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 22 5-6 (2002) 425-437
27. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 155 3 (2008) 308-315
28. Mansfield J.C., Parkes M., Hawthorne A.B., Forbes A., et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 26 3 (2007) 421-430
29. Prehn J.L., Landers C., Muller G.W., Man H.W., Stirling D.I., and Targan S.R. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 21 5 (2001) 357-364
30. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., and MacDonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108 4 (2001) 601-609
31. Meijer M.J., Mieremet-Ooms M.A., van Duijn W., van der Zon A.M., et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis (2006)
32. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 6 (1993) 1675-1680
33. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276 25 (2001) 22382-22387
34. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99 2 (1995) 160-167
35. Gockel H.R., Lugering A., Heidemann J., Schmidt M., et al. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 172 8 (2004) 5103-5109
36. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 9 (1994) 4082-4085
37. Kruse F.E., Joussen A.M., Rohrschneider K., Becker M.D., and Volcker H.E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236 6 (1998) 461-466
38. Dastidar S.G., Rajagopal D., and Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8 5 (2007) 364-372
39. Hartmann G., Bidlingmaier C., Siegmund B., Albrich S., et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 292 1 (2000) 22-30
40. Videla S., Vilaseca J., Medina C., Mourelle M., et al. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther 316 2 (2006) 940-945
41. Schreiber S., Keshavarzian A., Isaacs K.L., Schollenberger J., et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132 1 (2007) 76-86
42. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., and Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40 4 (1997) 470-474
43. Molostvov G., Morris A., Rose P., Basu S., and Muller G. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Br J Haematol 124 3 (2004) 366-375
44. Bartlett J.B., Tozer A., Stirling D., and Zeldis J.B. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93 6 (2005) 613-619
45. Richardson P.G., Blood E., Mitsiades C.S., Jagannath S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 10 (2006) 3458-3464